Expanding the clinical spectrum of late-onset Pompe disease: Dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered

Molecular Genetics and Metabolism

Volumn 103, Issue 4, 2011, Pages 362-366

  El Gharbawy, Areeg H ^a   Bhat, Gifty ^b   Murillo, Jaime E ^c   Thurberg, Beth L ^d   Kampmann, Christoph ^e   Mengel, Karl Eugen ^f   Kishnani, Priya S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d GENZYME CORPORATION   (United States)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Ascending aortic aneurysm; Dilated arteriopathy; Late onset Pompe

Indexed keywords

ADULT; AORTA; AORTA ANEURYSM; AORTA DISSECTION; ARTERY DILATATION; ARTERY DISEASE; ARTICLE; ASCENDING AORTA; BASILAR ARTERY; BICUSPID AORTIC VALVE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DILATED ARTERIOPATHY; DURAL ECTASIA; ECHOCARDIOGRAPHY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMAGE ANALYSIS; MAGNETIC RESONANCE ANGIOGRAPHY; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; THORACIC AORTA; THORAX RADIOGRAPHY;

ADULT; AORTA, THORACIC; AORTIC DISEASES; CHILD, PRESCHOOL; DILATATION, PATHOLOGIC; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MIDDLE AGED; PHENOTYPE;

EID: 79960840965     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.04.009     Document Type: Article

References (19)

1. Hirschhorn R., Reuser A.J.J. Glycogen storage disease type II. Acid alpha-glucosidase (acid maltase) deficiency. The Metabolic and Molecular Bases of Inherited Disease 2001, vol. III:3389-3420. MacGraw-Hill, New York. 8th ed. C. Scriver, A. Beaudet, W. Sly, D. Valle (Eds.).
2. Winkel L.P.F., Hagemans M.L.C., van Doorn P.A., Loonen M.C., Hop W.J., Reuser A.J., et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J. Neurol. 2005, 252:875-884.
3. Sacconi S., Bocquet J.D., Chanalet S., Tanant V., Salviati L., Desnuelle C. Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease. J. Neurol. 2010, 257(10):1730-1733.
4. Braunsdorf W.E. Fusiform aneurysm of basilar artery and ectatic internal carotid arteries associated with glycogenosis type 2 (Pompe's disease). Neurosurgery 1987, 21:748-749.
5. Laforet P., Petiot P., Nicolino M., Orlikowski D., Caillaud C., et al. Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease. Neurology 2008, 70(22):2063-2066.
6. Barbey F., Quanadli S.D., Juli C., Brakch N., Palacek T., et al. Aortic remodelling in Fabry disease. Eur. Heart J. 2010, 31:347-353.
7. Nemes A., Soliman O.I., Geleijnse M.L., Anwar A.M., van der Beek N.A., et al. Increased aortic stiffness in glycogenosis type 2 (Pompe's disease). Int. J. Cardiol. 2007, 120:138-141.
8. Kishnani P.S., Steiner R.D., Bali D., Berger K., et al. Pompe disease diagnosis and management guideline. Genet. Med. 2006, 8:267-288.
9. Isselbacher E.M. Thoracic and abdominal aortic aneurysms. Circulation 2005, 111:816-828.
10. Wolak A., Gransar H., Thomson L.E.J., Friedman J.D., Hachamovitch R., et al. Aortic size assessment by noncontrast cardiac computed tomography: normal limits by age, gender, and body surface area. JACC: Cardiovasc. Imaging 2008, 1(2):200-209.
11. Thurberg B.L., Maloney C.L., Vaccaro C., Afonso K., Tsai A.C., et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab. Invest. 2006, 86(12):1208-1220.
12. Guo D., Hasham S., Kuang S.-Q., Vaughan C.J., Boerwinkle E., et al. Familial thoracic aortic aneurysms and dissections. Circulation 2001, 103:2461-2468.
13. Allaire E., Schneider F., Saucy F., Dai J., Cochennec F., et al. New insight in aetiopathogenesis of aortic diseases. Eur. J. Vasc. Endovasc. Surg. 2009, 37:531-537.
14. Winkel L.P., Kamphoven J.H., van den Hout H.J., Severijnen L.A., van Doorn P.A., et al. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy. Muscle Nerve 2003, 27:743-751.
15. Kobayashi H., Shimada Y., Ikegami M., Kawai T., Sakurai K., et al. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case. Mol. Genet. Metab. 2010, 100:14-19.
16. Bijvoet A.G., Van Hirtum H., Vermey M., Van Leenen D., Van Der Ploeg A.T., et al. Pathological features of glycogen storage disease type II highlighted in the knockout mouse model. J. Pathol. 1999, 189:416-424.
17. Lynch C.M., Johnson J., Vaccaro C., Thurberg B.L. High resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology. J. Histochem. Cytochem. 2005, 53(1):63-73.
18. Brooke B.S., Habashi J.P., Judge D.P., Patel N., Loeys B., Dietz H.C. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N. Engl. J. Med. 2008, 358:2787-2795.
19. Kabirdas D., Scridon C., Brenes J.C., Hernandez A.V., Novaro G.M., Asher C.R. Accuracy of transthoracic echocardiography for the measurement of the ascending aorta: comparison with transesophageal echocardiography. Clin. Cardiol. 2010, 33(8):502-507.